Research method
Single-cell RNA-seq (scRNA-seq)
4 studies
Single-cell RNA-seq measures transcriptomes of individual cells so heterogeneous tissues, organoids, or tumors are not averaged into one bulk profile. In this library it appears in stem-cell differentiation, vascularized brain organoids, and a colorectal cancer atlas.
Students meet scRNA-seq as a magic atlas button. Real papers use it for different claims—lineage transitions, organoid cell states, or tumor/stroma stratification—that should stay separated.
Studies
4
Findings
4
4 supporting · 0 challenging · 4 qualifying citations
Open tensions
2
Currently
What we know
- scRNA-seq can separate definitive endoderm progenitors and point to hypoxia effects in hESC cultures.
- In vascularized cortical organoids, scRNA-seq tracks neurogenesis and vessel-related programs.
- A CRC single-cell atlas links CMS labels to immune/stromal states and outcomes.
- snRNA-seq maps end-stage ischemic cardiomyopathy cell states.
Largest unresolved question
hESC endoderm time courses, brain organoid atlases, and CRC tumor atlases all use scRNA-seq without answering the same biological question—do not average their findings into one ‘scRNA-seq result.’
Common misconceptions
scRNA-seq always yields one clean cell-type map that replaces bulk CMS or FACS markers.
Atlases can show continua and intratumoral heterogeneity; CMS labels still appear as mixed states within tumors.
If a paper mentions scRNA-seq, it is automatically a good undergraduate study card on the method alone.
Many high-citation ‘scRNA’ hits are software toolboxes; this page privileges empirical biology papers with clear findings.
Related
Claim ledger
What the evidence shows
Drawn from 4 studies in this library. Mix labels say which citation roles are present; they are not a strength score. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope.
scRNA-seq can separate definitive endoderm progenitors and point to hypoxia effects in hESC cultures.
In human ES differentiation, scRNA-seq separated definitive endoderm progenitors (PC5 signature) and motivated severe hypoxia experiments that increased CXCR4+ DE-like cells.
- Vascularized brain organoids tracked with scRNA-seq— different system — cortical organoids, not hESC endoderm
- A single-cell atlas refines colorectal cancer subtypes— different system — CRC tumor atlas, not stem-cell DE
Study Role Design N Population Outcome What marks definitive endoderm progenitors in hESCs? Supports Animal / in-vitroscRNA-seq of H1/H9 progenitors and oxygen-condition tests during definitive endoderm differentiation N=1018 · 1,018 single cells analysed (including H1 n=212, H9 n=162, HFFs n=159) Human embryonic stem cells and lineage-specific progenitors Single-cell regulators and hypoxia effects on definitive endoderm differentiation Vascularized brain organoids tracked with scRNA-seq Qualifiesdifferent system — cortical organoids, not hESC endoderm Animal / in-vitroVascularized human cortical organoids with electrophysiology, scRNA-seq, and mouse S1 transplant Organoid cultures maintained >200 days — no single primary analytic N in stored text Human cortical organoids (vOrganoids) and mouse graft hosts Vascularization, synapses, and graft–host vessel formation in cortical organoids A single-cell atlas refines colorectal cancer subtypes Qualifiesdifferent system — CRC tumor atlas, not stem-cell DE OtherSingle-cell atlas of CRC tumor/microenvironment relative to CMS, with external cohorts N=16 · 16 primary patients (plus adjacent normals); ~487,829 cells across pooled cohorts Racially diverse CRC patients and external single-cell CRC cohorts Cellular CMS heterogeneity and CAF/C1Q+ TAM contributions to prognosis In vascularized cortical organoids, scRNA-seq tracks neurogenesis and vessel-related programs.
Single-cell RNA-seq of vOrganoids illustrated robust neurogenesis and differentially expressed genes related to blood-vessel morphogenesis, alongside synaptic physiology and transplant vessel formation.
- What marks definitive endoderm progenitors in hESCs?— different developmental lineage question
Study Role Design N Population Outcome Vascularized brain organoids tracked with scRNA-seq Supports Animal / in-vitroVascularized human cortical organoids with electrophysiology, scRNA-seq, and mouse S1 transplant Organoid cultures maintained >200 days — no single primary analytic N in stored text Human cortical organoids (vOrganoids) and mouse graft hosts Vascularization, synapses, and graft–host vessel formation in cortical organoids What marks definitive endoderm progenitors in hESCs? Qualifiesdifferent developmental lineage question Animal / in-vitroscRNA-seq of H1/H9 progenitors and oxygen-condition tests during definitive endoderm differentiation N=1018 · 1,018 single cells analysed (including H1 n=212, H9 n=162, HFFs n=159) Human embryonic stem cells and lineage-specific progenitors Single-cell regulators and hypoxia effects on definitive endoderm differentiation A CRC single-cell atlas links CMS labels to immune/stromal states and outcomes.
Across ~487,829 cells, tumor cells recapitulated CMS subgroups with intratumoral heterogeneity; MSI-H tumors showed CD8 cytotoxic infiltration patterns; high CAF and C1Q+ TAM content associated with poorer outcomes.
- Vascularized brain organoids tracked with scRNA-seq— different tissue — brain organoid model, not CRC
Study Role Design N Population Outcome A single-cell atlas refines colorectal cancer subtypes Supports OtherSingle-cell atlas of CRC tumor/microenvironment relative to CMS, with external cohorts N=16 · 16 primary patients (plus adjacent normals); ~487,829 cells across pooled cohorts Racially diverse CRC patients and external single-cell CRC cohorts Cellular CMS heterogeneity and CAF/C1Q+ TAM contributions to prognosis Vascularized brain organoids tracked with scRNA-seq Qualifiesdifferent tissue — brain organoid model, not CRC Animal / in-vitroVascularized human cortical organoids with electrophysiology, scRNA-seq, and mouse S1 transplant Organoid cultures maintained >200 days — no single primary analytic N in stored text Human cortical organoids (vOrganoids) and mouse graft hosts Vascularization, synapses, and graft–host vessel formation in cortical organoids snRNA-seq maps end-stage ischemic cardiomyopathy cell states.
Profiling ~100k human cardiac nuclei showed fewer cardiomyocytes and more specialized endothelial states in ICM versus non-failing controls, with programs overlapping other end-stage cardiomyopathies.
Debates
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes.
hESC endoderm time courses, brain organoid atlases, and CRC tumor atlases all use scRNA-seq without answering the same biological question—do not average their findings into one ‘scRNA-seq result.’
hESC endoderm time courses, brain organoid atlases, and CRC tumor atlases all use scRNA-seq without answering the same biological question—do not average their findings into one ‘scRNA-seq result.’
- What marks definitive endoderm progenitors in hESCs?
- A single-cell atlas refines colorectal cancer subtypes
Study Role Design N Population Outcome What marks definitive endoderm progenitors in hESCs? Supports Animal / in-vitroscRNA-seq of H1/H9 progenitors and oxygen-condition tests during definitive endoderm differentiation N=1018 · 1,018 single cells analysed (including H1 n=212, H9 n=162, HFFs n=159) Human embryonic stem cells and lineage-specific progenitors Single-cell regulators and hypoxia effects on definitive endoderm differentiation A single-cell atlas refines colorectal cancer subtypes Supports OtherSingle-cell atlas of CRC tumor/microenvironment relative to CMS, with external cohorts N=16 · 16 primary patients (plus adjacent normals); ~487,829 cells across pooled cohorts Racially diverse CRC patients and external single-cell CRC cohorts Cellular CMS heterogeneity and CAF/C1Q+ TAM contributions to prognosis
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
Method papers and toolboxes in the wider queue are not interchangeable with these empirical atlases; this page only cites studies that make a biological claim with single-cell profiles.
Method papers and toolboxes in the wider queue are not interchangeable with these empirical atlases; this page only cites studies that make a biological claim with single-cell profiles.
- Vascularized brain organoids tracked with scRNA-seq
- A single-cell atlas refines colorectal cancer subtypes
Study Role Design N Population Outcome Vascularized brain organoids tracked with scRNA-seq Supports Animal / in-vitroVascularized human cortical organoids with electrophysiology, scRNA-seq, and mouse S1 transplant Organoid cultures maintained >200 days — no single primary analytic N in stored text Human cortical organoids (vOrganoids) and mouse graft hosts Vascularization, synapses, and graft–host vessel formation in cortical organoids A single-cell atlas refines colorectal cancer subtypes Supports OtherSingle-cell atlas of CRC tumor/microenvironment relative to CMS, with external cohorts N=16 · 16 primary patients (plus adjacent normals); ~487,829 cells across pooled cohorts Racially diverse CRC patients and external single-cell CRC cohorts Cellular CMS heterogeneity and CAF/C1Q+ TAM contributions to prognosis
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
Timeline
How understanding moved
Study years are when the paper was published. Evidence edits are dated changes to this page's claims. Explanations are when PaperFren added a Discovery — not a claim that the science happened that day.
2026
- Added a supporting study
What cell programs mark ischemic cardiomyopathy?
Concept page published
Single-cell RNA-seq (scRNA-seq)
New claim
Profiling ~100k human cardiac nuclei showed fewer cardiomyocytes and more specialized endothelial states in ICM versus non-failing controls, with programs overlapping other end-stage cardiomyopathies.
- Added a supporting study
What cell programs mark ischemic cardiomyopathy?
New claim
Profiling ~100k human cardiac nuclei showed fewer cardiomyocytes and more specialized endothelial states in ICM versus non-failing controls, with programs overlapping other end-stage cardiomyopathies.
Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Coverage edits are distinct from reviewed research changes and corrections. Dates record PaperFren updates; study publication dates appear in the timeline.
Profiling ~100k human cardiac nuclei showed fewer cardiomyocytes and more specialized endothelial states in ICM versus non-failing controls, with programs overlapping other end-stage cardiomyopathies.
- Coverage updated · New claim
- Coverage updated · Added a supporting study: What cell programs mark ischemic cardiomyopathy?
- Coverage updated · Concept page published
Profiling ~100k human cardiac nuclei showed fewer cardiomyocytes and more specialized endothelial states in ICM versus non-failing controls, with programs overlapping other end-stage cardiomyopathies.
- Coverage updated · New claim
- Coverage updated · Added a supporting study: What cell programs mark ischemic cardiomyopathy?
Papers
4 studies in this library bear on Single-cell RNA-seq (scRNA-seq), ordered by citations.
- What marks definitive endoderm progenitors in hESCs?
Single-cell RNA-seq separates definitive endoderm progenitors and links metabolism/hypoxia to DE differentiation.
- Vascularized brain organoids tracked with scRNA-seq
Human cortical vOrganoids kept for >200 days show cortical cell types, vessel-like structure, synapses, and scRNA-seq neurogenesis/vessel programs; grafts form functional human–mouse vessels in mouse S1 cortex.
- A single-cell atlas refines colorectal cancer subtypes
Across ~487,829 cells from diverse CRC samples and cohorts, tumors show CMS-related programs plus immune/stromal continua; high CAF and C1Q+ TAM content track poorer outcomes and may simplify prognosis beyond bulk CMS alone.
- What cell programs mark ischemic cardiomyopathy?
snRNA-seq of ~100k cardiac nuclei showed fewer cardiomyocytes and more specialized endothelial states in ICM, overlapping other end-stage cardiomyopathy programs.
Compare studies
Select 2–10 studies. Design and N are labels, not a ranking.
Nothing selected yet.
Questions
What is still open
hESC endoderm time courses, brain organoid atlases, and CRC tumor atlases all use scRNA-seq without answering the same biological question—do not average their findings into one ‘scRNA-seq result.’
Method papers and toolboxes in the wider queue are not interchangeable with these empirical atlases; this page only cites studies that make a biological claim with single-cell profiles.
Ask PaperFren about Single-cell RNA-seq (scRNA-seq)
Study this conceptflashcards and short-answer questions
Give two different scientific questions scRNA-seq answers in this library.
Examples: when mesendoderm transitions to definitive endoderm in hESCs; which immune/stromal states track CRC outcomes beyond bulk CMS.
Why can CAF/TAM signatures refine CMS prognosis claims?
Because bulk subtype labels mix tumor and stroma; single-cell maps let authors attribute risk to specific fibroblast and macrophage states.